US 12,433,859 B2
Oral solutions comprising lisdexamfetamine salts
Georgios Liolios, Chalandri Attica (GR); and Ioannis Psarrakis, Lavrion (GR)
Assigned to Adalvo Limited, San Gwann (MT)
Filed by Adalvo Limited, San Gwann (MT)
Filed on Aug. 2, 2024, as Appl. No. 18/792,999.
Application 18/792,999 is a continuation of application No. 18/167,634, filed on Feb. 10, 2023.
Application 18/167,634 is a continuation of application No. 16/961,784, granted, now 11,576,878, issued on Feb. 14, 2023, previously published as PCT/EP2020/060777, filed on Apr. 16, 2020.
Claims priority of application No. 19386059 (EP), filed on Dec. 30, 2019.
Prior Publication US 2024/0390304 A1, Nov. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/165 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01)
CPC A61K 31/165 (2013.01) [A61K 9/0053 (2013.01); A61K 9/08 (2013.01)] 22 Claims
 
1. An oral pharmaceutical solution comprising 10 mg/ml of lisdexamfetamine dimesylate and a pharmaceutically acceptable aqueous carrier comprising a buffer and a non-aqueous cosolvent selected from a glycol, a polyol and a mixture thereof, wherein the pH of the solution is from 6.0 to 9.0, and wherein the solution contains less than 1.0% total impurities after four weeks.